Possibly — but there are few reports. 100% of 9 people who reported on ALA for blood sugar say it improved. 0% noticed no change and 0% say it got worse.
Conclusion: ALA treatment had favorable effects on DSPN by reducing sensory symptoms, and it resulted in a dose-dependent response relative to the placebo for TSS and the global satisfaction score. The use of ALA to prevent neurological symptoms should be further researched.
Conclusion: Our analysis suggests that ALA probably has little or no effect on neuropathy symptoms or adverse events at six months, and may have little or no effect on impairment at six months. All the studies were at high risk of attrition bias. Therefore, future RCTs should ensure complete follow-up and transparent reporting of any participants missing from the analyses.
Based on few reports — treat as anecdotal. Information only — not medical advice. How we count